Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms...
Gardado en:
| Publicado en: | Curr Control Trials Cardiovasc Med |
|---|---|
| Principais autores: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2001
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC59641/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11806792/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/cvm-2-4-171 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|